Descrizione del progetto
La medicina intercettiva basata sull’infiammazione nel diabete di tipo 2
Le persone con il diabete di tipo 2 non utilizzano in modo efficiente l’insulina e, pertanto, vedono salire i propri livelli di glucosio. Il diabete di tipo 2 è una malattia eterogenea, il che ostacola la somministrazione di un trattamento personalizzato ottimale. Di conseguenza, le traiettorie individuali dei pazienti, contraddistinte da un’iperglicemia progressiva e dal rischio di complicazioni croniche, tra cui ictus, infarti, nefropatia e retinopatia sono finora difficili da prevedere. Si ipotizza che l’infiammazione sistemica cronica sia un fattore importante per l’insorgenza e la progressione di tali complicazioni. Il progetto INTERCEPT-T2D, finanziato dall’UE, offrirà una nuova dimensione clinicamente rilevante per il trattamento del diabete di tipo 2, considerando al momento della diagnosi i parametri infiammatori che sono importanti per la transizione alle complicazioni correlate a questa patologia. Inoltre, il progetto contribuirà a fornire trattamenti ideali su misura delle esigenze dei pazienti e condurrà una sperimentazione clinica per valutare l’efficacia delle strategie antinfiammatorie.
Obiettivo
The overall concept of INTERCEPT-T2D is to establish whether an inflammatory-mediated profile contributes to the onset of Type 2 Diabetes (T2D) complications, thus enabling the identification of patients most at risk of complications and the design of personalized prevention measures.
T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycemia and risk of chronic complications are so far difficult to predict. In this context, onset of diabetic complications represents the most important transitional phase of T2D development toward premature disability and mortality.
Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. INTERCEPT-T2D will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. The combination of state-of-the-art genomics and cell-biology technologies with targeted clinical interventions should lead to potent patients’ stratification. It should allow the identification and prognosis of a novel class or subclass of patients characterized by an “Inflammatory-mediated T2D” endotype.
The project has access to the best-documented longitudinal human European cohorts of patients with T2D, with reliable clinical and biological data allowing to trace the transition and evolution towards organ complications. This, added to the exploitation of an extensive health data warehouse, will enable us to establish the inflammatory trajectory of citizens with T2D from diagnosis to the development of complications.
To explore the ability to prevent the transition phase of T2D towards organ complications, INTERCEPT-T2D will conduct a phase II clinical trial with an anti-inflammatory therapy targeting NLRP3 Inflammasome activity in patients with T2D.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
75654 Paris
Francia